RecruitingPhase 2NCT06341426

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)


Sponsor

University Health Network, Toronto

Enrollment

92 participants

Start Date

Feb 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD). Researchers also want to know if a second dose of psilocybin is safe and well-tolerated. This study will see if psilocybin is effective, safe, and well-tolerated by tracking changes in depressive symptoms, suicidality, and side effects. This study will also see if a second dose of psilocybin has an effect on quality of life, functioning, cognition (thinking, reasoning, remembering), and how long depressive symptoms improve (or worsen) after psilocybin is administered.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether one or two doses of psilocybin (a psychedelic compound) combined with psychotherapy works better for people with treatment-resistant depression — meaning depression that hasn't improved with at least two different antidepressant medications. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with moderate to severe major depressive disorder (not with psychosis) - You have tried at least two antidepressant medications without enough improvement - You can read and communicate in English - You are able to swallow oral medication - You agree to use effective contraception if applicable **You may NOT be eligible if...** - You have a history of psychosis or schizophrenia - You have had drug or alcohol dependence in the past 3 months - You are at high risk of suicide requiring immediate treatment - You have a significant neurological condition like epilepsy - You have a pacemaker, metal implants in your skull, or are unsuitable for MRI - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSingle Psychedelic Dose Psilocybin

One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy

DRUGTwo Psychedelic Doses Psilocybin

Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy


Locations(1)

Toronto Western Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06341426


Related Trials